News | Nuclear Imaging | February 14, 2020

Sirtex Medical announces collaboration with MIM Software Inc.

Partnership advances innovation and increases precision of liver-directed oncology therapies for patients

SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.

February 14, 2020 —  Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. Under the terms of the agreement, Sirtex's specialized sales teams in the United States, Europe and other key global markets will offer MIM SurePlan LiverY90 software alongside the company's SIR-Spheres Y-90 resin microspheres to improve treatment precision for patients with hepatic tumors.

MIM SurePlan LiverY90 provides timesaving tools and post-treatment dosimetry for interventional radiologists and nuclear medicine physicians treating hepatic tumors with SIR-Spheres. The software allows physicians to quickly calculate the dose delivered by the microspheres to improve treatment decisions and patient care. The technology also incorporates CT, PET, SPECT and MRI scans simultaneously to deliver results on spheres deposition, coverage and absorbed dose, allowing physicians to make informed decisions faster about next steps. 

In addition to sharing a mission to provide physicians the tools they need to treat cancers, Sirtex and MIM also share a commitment to provide patients the best care throughout the treatment journey.

"Given the overlap of their technology and our SIR-Spheres product, Sirtex and MIM have a long history of working alongside clinical care teams," said Kevin Smith, chief executive officer of Sirtex. "Now as partners, we will be able to combine our expertise and resources to provide an even higher level of support to treat liver tumors. We are excited to see how this collaboration will benefit physicians and ultimately improve treatment outcomes for patients."

"We are proud and excited to partner with Sirtex, mainly because it will provide access to personalized dosimetry for a large number of patients across the globe," said Andrew Nelson, chief executive oficer of MIM Software Inc. "The treatment of liver tumors requires a multi-disciplinary approach, so it's a natural evolution for companies like ours to partner to provide an even faster, higher level of support and resources to treatment teams."

In the United States, SIR-Spheres Y-90 resin microspheres received Premarket Approval (PMA) from the FDA and are indicated for the treatment of non-resectable metastatic liver tumors from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India and Singapore.

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres

SIR-Spheres Y-90 resin microspheres is a prescription device for the treatment of inoperable liver tumors. SIRT is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumors. SIRT is administered to patients by interventional radiologists and nuclear medicine physicians, who infuse millions of radioactive resin microspheres via a catheter into the liver arteries that supply blood to the tumors. By using the tumors' blood supply, the microspheres selectively target liver tumors with a dose of radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

For more information: www.sirtex.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 U.S. Surgeon General Jerome Adams, M.D., M.Ph demonstrates how the general public can make their own face masks for non-clinical use.

U.S. Surgeon General Jerome Adams, M.D., M.Ph. demonstrates how the general public can make their own face masks for non-clinical use.

News | Coronavirus (COVID-19) | April 04, 2020 | By Melinda Taschetta-Millane
April 4, 2020 — The Centers for Disease Control and Prevention (CDC)
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Jeannie Danker, M.D. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Jeannie Danker, M.D. Photo courtesy of The Ohio State University Wexner Medical Center

News | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane
April 3, 2020 — The radiology world has lost a dedicated leader due to...
An estimated 44 million people worldwide are currently living with Alzheimer’s disease, the most common form of dementia. About 5.8 million people in the United States live with the disease, where it is the sixth leading cause of death overall. While there is not yet a cure for Alzheimer’s, researchers are working to find treatment options to delay its onset and prevent it from developing.

Image courtesy of Insightec

Feature | Ultrasound Imaging | April 02, 2020 | By Katie Caron
An estimated 44 million people worldwide are currently living with...
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

News | Ultrasound Imaging | April 02, 2020
April 2, 2020 — Esaote, an Italian company among the world leader
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Updated CT scoring criteria from AJR considers both lobe involvement and changes in CT findings to quantitatively and accurately evaluate the progression of COVID-19 pneumonia

CT scoring criteria were applied to images from sequential chest CT examinations. A, Initial chest CT image obtained 2 days after onset of symptoms shows small region of subpleural ground-glass opacities in right lower lobe, for CT score of 1. B, Chest CT image obtained on day 3 of treatment shows slightly enlarged region of subpleural ground-glass opacities with partial crazy-paving pattern and consolidation, for CT score of 3. C, Chest CT image obtained on day 5 of treatment shows partial resolution of consolidation, for CT score of 2. D, Chest CT image obtained on day 14 of treatment shows continued resolution of consolidation with minimal residual ground-glass opacities, for CT score of 1. Image courtesy of American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 02, 2020
April 2, 2020 — Updated computed t...
Improvised PPE face mask worn by a radiology technologist during rounds atSen. Gerardo M. Roxas Memorial District Hospital in Iloilo City, Philippines. #COVID19 #Coronavirus #SARScov2

Improvised PPE face mask worn by a radiology technologist during rounds at Sen. Gerardo M. Roxas Memorial District Hospital in Iloilo City, Philippines.

Feature | Coronavirus (COVID-19) | April 02, 2020 | Dave Fornell, Editor
There has been an extraordinary demand for personal protective equipment (PPE) with the rapid spread of the novel ...